Liquid Chromatographic-Mass Spectrometry Analysis and Pharmacokinetic Studies of Erianin for Intravenous Injection in Dogs

Abstract

The purpose of the present study was to examine the pharmacokinetic characteristics of erianin (2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)-ethyl]-phenol, CAS 95041-90-0), a nature product extracted from Dendrobium chrysotoxum, having notable antitumour activity, after intravenous injection of erianin fat emulsion to beagle dogs. An HPLC-MS method was developed to analyze the erianin levels in dog plasma and validated in a pharmacokinetic study. Plasma profiles were obtained after intravenous injection of erianin fat emulsion at the doses 7.5, 15 and 30 mg/kg. The elimination half-life (t_1/2) values for erianin were estimated to be 1.41 ± 0.31, 1.66 ± 0.19, 1.60 ± 0.28 h, while the mean area under concentration-time curve (AUC_0–∞) values were 1021.3 ± 373.7, 2305.1 ± 597.0 and 3952.1 ± 378.2 ngh/ml, respectively. In conclusion, the present observations indicated that erianin plasma concentrations were clearly dose-proportional for the dose range studied. There was no gender difference in pharmacokinetics for erianin in male and female dogs.

Key words

Antitumour agents - CAS 95041-90-0 - Erianin, dog plasma, HPLC-ESI-MS, pharmacokinetics

• References

• 1 Ma GX, Xu GJ, Xu LS. Inhibitory effects of dendrobium chrysotoxum and its constituents on the mouse HePA and ESC. J China Pharm Univ. 1994; 25 (3) 188-9
• 2 Wang TS, Lu YM, Ma GX, Pan Y, Xu GJ, Xu LS et al. In vitro inhibition activities of leukemia K562 cells growth by constituents from. D. chrysotoxum. Nat Prod Res Dev. 1997; jun 9 (2) 2-3
• 3 Ma GX, LeBlanc GA. The activity of erianin and chrysotox-ine from dendrobium chrysotoxum to reverse multidrug resistance in B16/h MDR-1 cells. J Chinese Pharm Sci. 1998; 7 (3) 142-6
• 4 Li YM, Wang HY, Liu GQ. Erianin induces apoptosis in human leukemia HL-60 cells. Acta Pharmacol Sin. 2001; Nov 22 (ll) 1018-22
• 5 Gong YQ, Fan Y, Wu DZ, Yang H, Hu ZB, Wang ZT. In vivo and in vitro evaluation of erianin, a novel anti-angiogenic agent. Eur J Cancer. 2004; Jul 40 (10) 1554-65
• 6 Gong YQ, Fan Y, Liu L, Wu DZ, Chang Z, Wang ZT. Erianin induces a JNK/SAPK-dependent metabolic inhibition in human umbilical vein endothelial cells. In Vivo. 2004; Mar-Apr 18 (2) 223-8